» Articles » PMID: 35458556

Development of Robust Varicella Zoster Virus Luciferase Reporter Viruses for In Vivo Monitoring of Virus Growth and Its Antiviral Inhibition in Culture, Skin, and Humanized Mice

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2022 Apr 23
PMID 35458556
Authors
Affiliations
Soon will be listed here.
Abstract

There is a continued need to understand varicella-zoster virus (VZV) pathogenesis and to develop more effective antivirals, as it causes chickenpox and zoster. As a human-restricted alphaherpesvirus, the use of human skin in culture and mice is critical in order to reveal the important VZV genes that are required for pathogenesis but that are not necessarily observed in the cell culture. We previously used VZV-expressing firefly luciferase (fLuc), under the control of the constitutively active SV40 promoter (VZV-BAC-Luc), to measure the VZV spread in the same sample. However, the fLuc expression was independent of viral gene expression and viral DNA replication programs. Here, we developed robust reporter VZV viruses by using bacterial artificial chromosome (BAC) technology, expressing luciferase from VZV-specific promoters. We also identified two spurious mutations in VZV-BAC that were corrected for maximum pathogenesis. VZV with fLuc driven by ORF57 showed superior growth in cells, human skin explants, and skin xenografts in mice. The ORF57-driven luciferase activity had a short half-life in the presence of foscarnet. This background was then used to investigate the roles for ORF36 (thymidine kinase (TK)) and ORF13 (thymidylate synthase (TS)) in skin. The studies reveal that VZV-∆TS had increased sensitivity to brivudine and was highly impaired for skin replication. This is the first report of a phenotype that is associated with the loss of TS.

Citing Articles

Development of a reporter feline herpesvirus-1 for antiviral screening assays.

Yang J, Li L, Xu F, Jia F Vet Res. 2024; 55(1):167.

PMID: 39696698 PMC: 11654381. DOI: 10.1186/s13567-024-01430-7.


Longitudinal Monitoring of the Effects of Anti-Adenoviral Treatment Regimens in a Permissive In Vivo Model.

Tollefson A, Cline-Smith A, Spencer J, Ying B, Reyna D, Lipka E Viruses. 2024; 16(8).

PMID: 39205174 PMC: 11359180. DOI: 10.3390/v16081200.


Blank Spots in the Map of Human Skin: The Challenge for Xenotransplantation.

Cherkashina O, Morgun E, Rippa A, Kosykh A, Alekhnovich A, Stoliarzh A Int J Mol Sci. 2023; 24(16).

PMID: 37628950 PMC: 10454653. DOI: 10.3390/ijms241612769.


Prodrug Strategies for the Development of β-l-5-(()-2-Bromovinyl)-1-((2,4)-2-(hydroxymethyl)-1,3-(dioxolane-4-yl))uracil (l-BHDU) against Varicella Zoster Virus (VZV).

Singh U, Konreddy A, Kothapalli Y, Liu D, Lloyd M, Annavarapu V J Med Chem. 2023; 66(10):7038-7053.

PMID: 37140467 PMC: 10226046. DOI: 10.1021/acs.jmedchem.3c00545.

References
1.
Lu P, Hung M, Srivastav A, Grohskopf L, Kobayashi M, Harris A . Surveillance of Vaccination Coverage Among Adult Populations -United States, 2018. MMWR Surveill Summ. 2021; 70(3):1-26. PMC: 8162796. DOI: 10.15585/mmwr.ss7003a1. View

2.
Lebrun M, Thelen N, Thiry M, Riva L, Ote I, Conde C . Varicella-zoster virus induces the formation of dynamic nuclear capsid aggregates. Virology. 2014; 454-455:311-27. DOI: 10.1016/j.virol.2014.02.023. View

3.
Rowe J, Greenblatt R, Liu D, Moffat J . Compounds that target host cell proteins prevent varicella-zoster virus replication in culture, ex vivo, and in SCID-Hu mice. Antiviral Res. 2010; 86(3):276-85. PMC: 2866756. DOI: 10.1016/j.antiviral.2010.03.007. View

4.
Gershon A, Gershon M . Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev. 2013; 26(4):728-43. PMC: 3811230. DOI: 10.1128/CMR.00052-13. View

5.
Cai M, Wang S, Xing J, Zheng C . Characterization of the nuclear import and export signals, and subcellular transport mechanism of varicella-zoster virus ORF9. J Gen Virol. 2010; 92(Pt 3):621-6. DOI: 10.1099/vir.0.027029-0. View